Top-100 highest-cited original articles in inflammatory bowel disease

Objectives: The use of citation analysis to identify the first 100 papers in inflammatory bowel disease (IBD) provides unique insights into advances in disease understanding and subsequent follow-up treatment innovations over time. Methods: The Thomson Reuters Web of Science database with the search terms “inflammatory bowel disease” or “Crohn disease” or “ulcerative colitis” or “colitis” was used to identify all English language full manuscripts for the study. Title, first and senior authors, institution and department of first author, journal, country of origin, year, and topic of each manuscript were analyzed. Results: The top 100 manuscripts were published between 1955 and 2013. 224,809 eligible papers were returned and the median (range) citation number was 1028.5 (719–3957). The country and year with the greatest number of publications were the USA (n = 47), and 2007 (n = 11). Gastroenterology published the highest number of papers (n = 18, 21,083 citations) and The New England Journal of Medicine had the most citations (n = 13, 25,035 citations). Conclusions: This highly cited list of papers identifies the subjects and authors who have had the greatest impact on IBD research in the last decades, which serves as a reference for researchers and clinicians “highly citable” manuscripts.

[1]  Lu Gao,et al.  Top 100 Most-Cited Articles on Pituitary Adenoma: A Bibliometric Analysis. , 2018, World neurosurgery.

[2]  A. Malik,et al.  The top 100 most-cited articles on osteosarcoma: a bibliometric analysis , 2018 .

[3]  A. Frings,et al.  The top 100 papers in dry eye - A bibliometric analysis. , 2018, The ocular surface.

[4]  Sufian S. Ahmad,et al.  Gunshot induced injuries in orthopaedic trauma research. A bibliometric analysis of the most influential literature. , 2017, Orthopaedics & traumatology, surgery & research : OTSR.

[5]  C. Ponsioen,et al.  Suppression of anti‐drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.

[6]  J. Lewis,et al.  Diet as a Trigger or Therapy for Inflammatory Bowel Diseases. , 2017, Gastroenterology.

[7]  R. Leal,et al.  The Immunological Basis of Inflammatory Bowel Disease , 2016, Gastroenterology research and practice.

[8]  S. Ng,et al.  World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. , 2016, Journal of clinical gastroenterology.

[9]  A. Lozano,et al.  The Most Cited Works in Aneurysmal Subarachnoid Hemorrhage: A Bibliometric Analysis of the 100 Most Cited Articles. , 2016, World neurosurgery.

[10]  W. Lewis,et al.  The 100 most influential manuscripts in gastric cancer: A bibliometric analysis. , 2016, International journal of surgery.

[11]  R. Baldassano,et al.  Diet in the pathogenesis and treatment of inflammatory bowel diseases. , 2015, Gastroenterology.

[12]  N. Hotte,et al.  Fecal microbiota transplantation inducing remission in Crohn's colitis and the associated changes in fecal microbial profile. , 2014, Journal of clinical gastroenterology.

[13]  M. Tomita,et al.  Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells , 2013, Nature.

[14]  S. Danese,et al.  ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). , 2013, Journal of Crohn's & colitis.

[15]  P. Munkholm,et al.  Inflammatory bowel disease epidemiology , 2013, Current opinion in gastroenterology.

[16]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[17]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[18]  T. Macdonald.  New cytokine targets in inflammatory bowel disease. , 2011, Gastroenterology & hepatology.

[19]  R. Xavier,et al.  Genetics and pathogenesis of inflammatory bowel disease , 2011, Nature.

[20]  Richard A. Flavell,et al.  NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis , 2011, Cell.

[21]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[22]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[23]  S. Mazmanian,et al.  Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota , 2010, Proceedings of the National Academy of Sciences.

[24]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[25]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[26]  A. Kaser,et al.  Inflammatory bowel disease. , 2010, Annual review of immunology.

[27]  D. Patel,et al.  Publication and citation analysis of the Australian and New Zealand Journal of Ophthalmology and Clinical and Experimental Ophthalmology over a 10‐year period: the evolution of an ophthalmology journal , 2009, Clinical & experimental ophthalmology.

[28]  R. Xavier,et al.  Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43 , 2009, Nature.

[29]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[30]  S. Akira,et al.  Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production , 2008, Nature.

[31]  Sarah L. Brown,et al.  A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells , 2008, Nature.

[32]  J. Doré,et al.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.

[33]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[34]  S. Mazmanian,et al.  A microbial symbiosis factor prevents intestinal inflammatory disease , 2008, Nature.

[35]  R Balfour Sartor,et al.  Microbial influences in inflammatory bowel diseases. , 2008, Gastroenterology.

[36]  N. Pace,et al.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.

[37]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[38]  Alastair Forbes,et al.  Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility , 2007, Nature Genetics.

[39]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[40]  S. Carding,et al.  Inflammatory bowel disease: cause and immunobiology , 2007, The Lancet.

[41]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[42]  Judy H Cho,et al.  Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis , 2007, Nature Genetics.

[43]  Stefan Wirtz,et al.  Chemically induced mouse models of intestinal inflammation , 2007, Nature Protocols.

[44]  P. Mannon,et al.  The fundamental basis of inflammatory bowel disease. , 2007, The Journal of clinical investigation.

[45]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[46]  Thomas Lengauer,et al.  A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 , 2007, Nature Genetics.

[47]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[48]  R. Sartor.  Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[49]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[50]  T. Mcclanahan,et al.  IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. , 2006, The Journal of clinical investigation.

[51]  C. Manichanh,et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.

[52]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[53]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[54]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[55]  Richard A. Flavell,et al.  Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract , 2005, Science.

[56]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[57]  E. Loftus.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[58]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[59]  G. Bouma,et al.  The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.

[60]  M. Chamaillard,et al.  Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection* , 2003, The Journal of Biological Chemistry.

[61]  S. Foster,et al.  Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2 , 2003, The Journal of Biological Chemistry.

[62]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[63]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[64]  R. Colman,et al.  Experimental models of inflammatory bowel disease. , 2003, Archivum immunologiae et therapiae experimentalis.

[65]  M. Schein,et al.  One Hundred Citation Classics in General Surgical Journals , 2002, World Journal of Surgery.

[66]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[67]  Manfred Dietel,et al.  Mucosal flora in inflammatory bowel disease. , 2002, Gastroenterology.

[68]  R. Blumberg,et al.  The immunology of mucosal models of inflammation. , 2002, Annual review of immunology.

[69]  S. Fisher,et al.  Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations , 2001, The Lancet.

[70]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[71]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[72]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[73]  D. Podolsky,et al.  Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease , 2000, Infection and Immunity.

[74]  W. Fiers,et al.  Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. , 2000, Science.

[75]  P. Brigidi,et al.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[76]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[77]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[78]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[79]  Fiona Powrie,et al.  An Essential Role for Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation , 1999, The Journal of experimental medicine.

[80]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[81]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[82]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[83]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[84]  R. Sartor,et al.  Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.

[85]  C. Fiocchi.  Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[86]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[87]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[88]  M. Leach,et al.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. , 1996, The Journal of clinical investigation.

[89]  M. Neurath,et al.  Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. , 1996, Journal of immunology.

[90]  Jean Weissenbach,et al.  Mapping of a susceptibility locus for Crohn's disease on chromosome 16 , 1996, Nature.

[91]  K. Ewe,et al.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) , 1995, Clinical and experimental immunology.

[92]  M. Neurath,et al.  Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.

[93]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[94]  R. Coffman,et al.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. , 1994, Immunity.

[95]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[96]  R. Coffman,et al.  Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. , 1993, International immunology.

[97]  A. Feller,et al.  Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene , 1993, Cell.

[98]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[99]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[100]  D. Podolsky,et al.  Inflammatory bowel disease (1) , 1991, The New England journal of medicine.

[101]  H. Adami,et al.  Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.

[102]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[103]  T. Ohkusa,et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice , 1990 .

[104]  J. Wallace,et al.  Hapten-induced model of chronic inflammation and ulceration in the rat colon. , 1989, Gastroenterology.

[105]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[106]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[107]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[108]  T. Stossel,et al.  Volume: papers and academic promotion. , 1987, Annals of internal medicine.

[109]  K. Ewe,et al.  European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .

[110]  D. Ransohoff,et al.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.

[111]  B. Pasternack,et al.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.

[112]  R. Nicholls,et al.  Proctocolectomy without ileostomy for ulcerative colitis. , 1978, British medical journal.

[113]  D. Sachar,et al.  THE EXTRA-INTESTINAL COMPLICATIONS OF CROHN'S DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTS , 1976, Medicine.

[114]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[115]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .